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Abstract 
Background 
The prevalence of multimorbidity (the presence of two or more long-term conditions) is 
rising internationally. Multimorbidity affects patients by increasing their burden of 
symptoms, but is also likely to increase the self-care demands, or treatment burden, that they 
experience. Treatment burden refers to the effort expended in operationalising treatments, 
navigating healthcare systems and managing relations with healthcare providers. This is an 
important problem for people with chronic illness such as stroke. Polypharmacy is an 
important marker of both multimorbidity and burden of treatment. In this study, we examined 
the prevalence of multimorbidity and polypharmacy in a large, nationally representative 
population of primary care patients with and without stroke, adjusting for age, sex and 
deprivation. 
Methods 
A cross-sectional study of 1,424,378 participants aged 18 years and over, from 314 primary 
care practices in Scotland that were known to be demographically representative of the 
Scottish adult population. Data included information on the presence of stroke and another 39 
long-term conditions, plus prescriptions for regular medications. 
Results 
In total, 35,690 people (2.5%) had a diagnosis of stroke. Of the 39 comorbidities examined, 
35 were significantly more common in people with stroke. Of the people with a stroke, the 
proportion that had one or more additional morbidities present (94.2%) was almost twice that 
in the control group (48%) (odds ratio (OR) adjusted for age, sex and socioeconomic 
deprivation 5.18; 95% confidence interval (CI) 4.95 to 5.43). In the stroke group, 12.6% had 
a record of 11 or more repeat prescriptions compared with only 1.5% of the control group 
(OR adjusted for age, sex, deprivation and morbidity count 15.84; 95% CI 14.86 to 16.88). 
Limitations include the use of data collected for clinical rather than research purposes, a lack 
of consensus in the literature on the definition of certain long-term conditions, and the 
absence of statistical weighting in the measurement of multimorbidity, although the latter was 
deemed suitable for descriptive analyses. 
Conclusions 
Multimorbidity and polypharmacy were strikingly more common in those with a diagnosis of 
stroke compared with those without. This has important implications for clinical guidelines 
and the design of health services. 
Background 
Multimorbidity, defined as the presence of two or more long-term conditions, is becoming a 
global challenge for policy-makers, clinicians, and patients [1–3]. Treatment advances and 
increasing sub-specialisation of health services have improved functional outcomes for those 
with long-term conditions, but such changes have resulted in an increasing burden of 
treatment demands on patients, particularly those with multimorbidity [3,4]. Treatment 
burden is defined as the workload of healthcare for patients and the impact of this on their 
wellbeing [5]. It includes information gathering, attending multiple appointments, taking 
medications, enacting self-care, and, in countries that lack a health service that is free at the 
point of care, organising finances to pay for treatments [5–8]. There is a risk that patients 
become overburdened by their treatments, which can mean failure to adhere to management 
plans, thus resulting in ineffective treatment and wasted resources [3,9–11]. 
One aspect of treatment burden described above is polypharmacy, which can contribute to 
other treatment burdens such as adverse drug events [12,13]. Polypharmacy is most 
commonly defined as the use of multiple (usually five or ten) prescribed medications [14–
16]. Although there is no strong evidence to support the use of any particular threshold, the 
risk of drug-related problems seems to increase with each additional medication prescribed 
[17,18]. There is a known association between number of morbidities and polypharmacy [19–
21], with a study using routine Scottish health records finding that of those with two clinical 
conditions, 20.8% were receiving four to nine medications, and 1.1% were receiving ten or 
more medications; for patients with six or more comorbidities, these values were 47.7% and 
41.7%, respectively [19]. A systematic literature review investigating the relationship 
between the number of chronic conditions and healthcare utilisation outcomes found that 
about 60% of elderly respondents with zero or one condition reported taking prescription 
medications. This percentage went up to more than 90% for those with two or three 
conditions, and approached 100% for those with more than five conditions [20], supporting 
the premise that those with higher numbers of conditions to manage are more likely to 
experience higher levels of treatment burden [3]. Other aspects of treatment burden such as 
healthcare utilisation have also been shown to be associated with multimorbidity [20,22]. 
Stroke is a condition that can have a considerable impact on an individual’s life. A recent 
systematic review of the qualitative literature revealed that people who have had a stroke 
experience four main areas of treatment burden: making sense of stroke management and 
planning care, interacting with others, enacting management strategies, and reflecting on 
management [23]. Poor communication between patients and professionals was a common 
experience, exacerbated by fragmentation of health services and poor communication 
between healthcare providers themselves, aspects of stroke care likely to be exacerbated by 
multimorbidity [24–26]. Surprisingly, there has been limited exploration of multimorbidity or 
polypharmacy in people with stroke, the field being characterised by small-scale studies and a 
small number of conditions under examination [19,27–36]. Those studies that have examined 
stroke in relation to other long-term conditions have suggested that stroke is one of the 
diseases most significantly associated with polypharmacy [19,33], but there is a lack of large-
scale studies examining a broad range of medications and comorbidities. 
In the current study, using a large, nationally representative cross-sectional primary care 
dataset, we examined the prevalence of multimorbidity and polypharmacy in people with and 
without stroke. 
Methods 
Study design and participants 
This was a cross-sectional study based on a nationally representative dataset managed by the 
Primary Care Clinical Informatics Unit at the University of Aberdeen in Scotland. This fully 
anonymised dataset contains clinical data on all people that were alive and permanently 
registered with 314 primary care practices in Scotland on 31 March 2007. Comprising 
approximately one-third of the Scottish adult population, this sample has been shown to be 
representative of this population [37]. In the UK, registration with a medical practice is 
required for an individual to access National Health Service (NHS) healthcare in the 
community. It is estimated that over 98% of the population are registered with a medical 
practice [38], which systematically records information on each patient in an electronic 
medical record, for the purposes of registration and subsequent everyday medical care. We 
examined data extracted from medical records and collated for a previous study of 
multimorbidity that had examined the presence of forty conditions [1]. The NHS National 
Research Ethics Service approved the use of these data for research purposes. Patient consent 
was not deemed necessary due to full anonymisation of the data. 
Data collected and disease definition 
The data examined consisted of the following variables: sex, age, socioeconomic deprivation 
(measured from patients’ postcodes using the Carstairs score [39]), counts of regularly 
prescribed medications and the presence of 40 long-term conditions, including stroke. 
There is no ‘gold standard’ method for the measurement of multimorbidity, therefore the 
forty long-term conditions included had been chosen and defined based on a recent 
systematic review [40] and expert consensus [1]. Existing definitions for each long-term 
condition were used if possible, mainly those used in the Quality and Outcomes Framework 
(QOF) or by NHS Scotland [1,41,42]. If no standard definition was available, or there was 
concern about under-recording, then conditions were defined by the clinical members of the 
research team. For example, depression was defined as the presence of a QOF Read Code in 
the past year or receipt of four or more prescriptions for antidepressant drugs (excluding low-
dose tricyclics, which are usually used for chronic pain) in the past year [1]. The definitions 
of all morbidities examined are given in supplementary material (see Additional file 1). 
Comorbidity was measured using a count of long-term conditions [43], with morbidities 
being noted as either mental health or physical morbidities. The original analysis measured 
the presence of a combined group of stroke or transient ischaemic attack (TIA), but for the 
purposes of this analysis, the presence of stroke alone was defined using the QOF Business 
Rules code set [41], and TIA was ignored. 
As there are no standard definitions of regularly prescribed treatments or measure of 
polypharmacy, we utilised a count of current regular prescriptions, including tablets, inhalers, 
stoma care and topical therapies [17,18]. Regular (‘repeat’) prescriptions are clearly 
distinguished in UK general practice electronic medical records from one-off (‘acute’) 
prescriptions such as those for most antibiotics. For the purposes of this analysis, any regular 
prescription that was still active (that is, available for issue on request) on the date of 
extraction and that had been prescribed in the past 84 days was counted as current. This time 
frame was selected as this was the maximum length of a repeat prescription in Scotland at the 
time of data collection. 
Statistical analysis 
Analyses were predicated on a comparison of the characteristics of people with stroke (cases) 
and those without stroke (controls). First, the numbers of morbidities and prescribed 
medications in stroke cases and controls were calculated, and proportions within each group 
computed. Second, logistic regression, which produces ORs, was used to summarise the 
relationship between stroke and the presence of comorbidities and prescribed medications. 
ORs were initially unadjusted – for the purposes of comparison – then adjusted for the key 
confounding factors of age, sex and socioeconomic deprivation. Age and deprivation were 
used as continuous variables. Deprivation was measured using the Carstairs score, which is 
widely used in health research. The Carstairs score is based on four census indicators: low 
social class, lack of car ownership, overcrowding and male unemployment. The scores have 
been described as a measure that reflects access to ‘those goods and services, resources and 
amenities and of a physical environment which are customary in society’ [39]. The scores 
therefore cannot be described as a measure of the extent of an individual’s material 
wellbeing, but are rather a summary measure applied to populations contained within small 
geographic localities. Further adjustment for number of morbidities was made when 
polypharmacy was the characteristic of interest. Associations between numbers of 
morbidities and prescriptions were assessed using Spearman correlation coefficients. For the 
purposes of this analysis, a P < 0.05 was deemed statistically significant. All analyses were 
carried out using IBM Statistical Package for the Social Sciences (SPSS) Statistics software 
(V21). 
Results 
The analyses were based on 1,424,378 individuals (724,949 women) aged 18 years and over 
who were registered with a general practitioner. In total, 35,690 people (2.5%) had a 
diagnosis of stroke. As anticipated, the mean age of people in the stroke group (72.68 ± 
12.21) was higher than that of the controls 47.36 ± 17.93). For the demographic 
characteristics for each group, see Additional file 2. 
Comorbidities 
Table 1 shows the number and percent of total morbidities, physical morbidities and mental 
health morbidities in the stroke and control groups, along with ORs for stroke in relation to 
these variables. Multimorbidity was common in stroke: of the study members with stroke, the 
percentage that had one or more additional morbidities present (94.2%) was almost twice that 
in the control group (48%) (OR adjusted for age, sex and deprivation 5.18; 95% CI 4.95 to 
5.43). Disaggregating the data into type of morbidity revealed that physical morbidity was 
markedly more common in people with stroke (adjusted OR 4.50; 95% CI 4.31 to 4.68), and 
mental health morbidity was also more common but the relationship was less strong (adjusted 
OR 2.10; 95% CI 2.05 to 2.15). In terms of assessing whether these differences exist across 
different age groups, a sub-analysis for age groups 35–44 years and 75+ years was performed 
(see Additional file 3). This indicated that differences were larger for the younger age group, 
and increased with the number of conditions (a similar picture was found for number of 
repeat prescriptions). However, the skewed distribution of stroke prevalence towards the 
oldest age groups make any assessment of differences by age problematic, owing to the small 
sample sizes in the youngest age groups. 
Table 1 Stroke status and number of morbidities (N = 1,424,378) 
 Stroke N (%) No stroke (%) Unadjusted OR (95% CI) a Age, gender and deprivation 
adjusted OR (95% CI) a 35690 (100) 1388688 (100) 
Total number of morbiditiesb     
None 2053 (5.8) 721430 (52.0) 1 1 
One-three 17750 (49.7) 551295 (39.7) 11.31 (10.81 to 11.85) 4.35 (4.15 to 4.56) 
Four-six 12300 (34.5) 100500 (7.2) 43.01 (41.03 to 45.09) 8.59 (8.17 to 9.04) 
Seven or more 3587 (10.1) 15463 (1.1) 81.52 (77.04 to 86.26) 12.81 (12.05 to 13.61) 
Number of physical morbiditiesb     
None 2769 (7.8) 800202 (57.6) 1 1 
One-three 20716 (58.0) 510846 (36.8) 11.72 (11.26 to 12.20) 4.03 (3.86 to 4.20) 
Four-six 10414 (29.2) 70709 (5.1) 42.56 (40.79 to 44.41) 7.32 (6.99 to 7.67) 
Seven or more 1791 (5.0) 6931 (0.5) 74.68 (70.05 to 79.61) 10.33 (9.64 to 11.05) 
Number of mental morbidities     
None 21961 (61.5) 1163095 (83.8) 1 1 
One-three 13533 (37.9) 223739 (16.1) 3.20 (3.13 to 3.27) 2.08 (2.04 to 2.13) 
Four or more 196 (0.5) 1854 (0.1) 5.60 (4.83 to 6.49) 3.56 (3.03 to 4.20) 
a
 all p < 0.001. 
b
 excluding stroke. 
The ten most frequent comorbidities present in people with a diagnosis of stroke were: 
hypertension (60.9%), coronary heart disease (29.5%), painful condition (21.9%), depression 
(20.7%), diabetes (18.8%), chronic kidney disease (14.3%), constipation (13.8%), atrial 
fibrillation (13.0%), thyroid disorders (11.9 %), and chronic obstructive pulmonary disease 
(11.9%). Prevalences of all morbidities are shown in supplementary material (see Additional 
files 4 and 5). 
Figure 1 displays the ORs (adjusted for age, sex and deprivation) for stroke in relation to the 
thrity one physical morbidities examined. The supplementary material (see Additional file 4) 
elaborates on this by showing both the unadjusted and adjusted ORs along with the crude 
prevalence of all physical morbidities in the stroke and control groups. In all, twenty eight of 
the thirty one physical morbidities examined were significantly more common in the stroke 
group, this was twenty seven after adjustment for potential confounding factors. For instance, 
epilepsy (adjusted OR 4.43; 95% CI 4.14 to 4.74), hypertension (adjusted OR 2.67; 95% CI 
2.61 to 2.73), peripheral vascular disease (adjusted OR 2.47; 95% CI 2.37 to 2.58), AF 
(adjusted OR 2.44; 95% CI 2.36 to 2.53) and CHD (adjusted OR 2.06; 95% CI 2.01 to 2.11) 
were all more common in people experiencing a cerebrovascular disease event. By contrast, 
dyspepsia was markedly less common in the stroke group (adjusted OR 0.63; 95% CI 0.60 to 
0.66). Figure 2 shows the ORs (adjusted for age, sex and deprivation) for stroke in relation to 
eight mental health morbidities. The unadjusted and adjusted ORs, along with the crude 
prevalence of all mental health morbidities in the stroke and stroke-free groups, are shown in 
supplementary material (see Additional file 5). In all, six of the eight mental health 
morbidities examined were significantly more common in the stroke group, and following 
adjustments, all eight mental health morbidities were significantly more common. These 
included drug and medication use problems (adjusted OR 2.34; 95% CI 2.25 to 2.43), 
depression (adjusted OR 2.09; 95% CI 2.03 to 2.15), alcohol problems (adjusted OR 2.05; 
95% CI 1.96 to 2.15) and anxiety and stress (adjusted OR 1.61; 95% CI 1.55 to 1.66). 
Figure 1 Odds ratios (with 95% Cl) for physical morbidities in relation to stroke status 
(adjusted for age, sex, and deprivation). The stroke group comprised 35,690 people, and 
the stroke-free group comprised 1,388,688 people. 
Figure 2 Odds ratios (with 95% Cl) for mental health morbidities in relation to stroke 
status (adjusted for age, sex, and deprivation). The stroke group comprised 35,690 people, 
and the stroke-free group comprised 1,388,688 people. 
Regular prescriptions 
As anticipated, the number of regular prescriptions was significantly correlated with number 
of morbidities in the stroke (Spearman’s ρ = 0.58 P < 0.001) and control (Spearman’s ρ = 
0.75 P < 0.001) groups. Table 2 shows the number of repeat prescriptions in the stroke and 
control groups, and the ORs. Those with stroke were more likely than the controls to be on a 
repeat prescription (adjusted OR 4.53; 95% CI 4.33 to 4.74). In the stroke group, 12.6% had 
eleven or more repeat prescriptions compared with only 1.5% of the control group (OR 
adjusted for age, sex, deprivation and morbidity count 15.84; 95% CI 14.86 to 16.88). 
Table 2 Stroke status and number of repeat medications (N = 1,424,378) 
a
 all p < 0.001. 
Discussion 
Summary of findings and implications 
Analyses of a large, nationally representative sample of people in Scotland, a country with 
universal healthcare, showed that multimorbidity and polypharmacy were more common in 
people with a diagnosis of stroke. These findings are consistent with our knowledge that 
those with stroke are an elderly population with considerable cardiovascular disease risk [44], 
for whom effective treatments are increasingly available to alleviate symptoms and address 
underlying causal factors [45]. Diagnoses of most chronic conditions were more common in 
the stroke group, and this remained the case after adjustment for age, sex and deprivation. In 
our preliminary analyses (see Additional file 2), both age and deprivation were associated 
with stroke in the expected directions. This gives us confidence in the novel results presented 
herein. 
Polypharmacy represents only one aspect of treatment burden, but is directly measurable, and 
may be a proxy measure of wider aspects of burden [17,18]. Multimorbidity is likely to 
increase treatment burden in several ways. First, as this study and others have shown, the 
number of medications increases with number of conditions [20,21]. Second, treatments may 
interact, leading to side effects [5,7,46] and this has the potential to further increase the 
 Stroke N (%) No stroke N (%) Unadjusted OR (95% CI) a Age, gender and deprivation 
adjusted OR (95% CI) a 
Age, gender, deprivation and morbidity 
count adjusted OR (95% CI) a 35690 (100) 1388688 (100) 
Number of medications      
None 2447 (6.9%) 863688 (62.2%) 1 1 1 
One-two 3038 (8.5%) 240721 (17.3%) 4.45 (4.22 to 4.70) 2.38 (2.26 to 2.52) 2.29 (2.17 to 2.42) 
Three-four 6566 (18.4%) 122518 (8.8%) 18.92 (18.05 to 19.82) 6.25 (5.95 to 6.57) 5.78 (5.49 to 6.08) 
Five-six 8185 (22.9%) 75512 (5.4%) 38.26 (36.55 to 40.05) 10.50 (9.99 to 11.03) 9.36 (8.89 to 9.86) 
Seven-eight 6721 (18.8%) 43344 (3.1%) 54.73 (52.20 to 57.38) 13.90 (13.20 to 14.63) 11.94 (11.29 to 12.62) 
Nine-ten 4219 (11.8%) 22536 (1.6%) 66.08 (62.76 to 69.57) 16.22 (15.34 to17.15) 13.44 (12.65 to 14.29) 
Eleven or more 4514(12.6%) 20369 (1.5%) 78.22 (74.32 to 82.32) 20.13 (19.05 to 21.27) 15.84 (14.86 to 16.88) 
volume of work; for example, as new treatments are given to compensate for interactions 
[47]. Third, multimorbidity is likely to increase healthcare contacts and affect the capacity of 
the individual to follow therapeutic regimens [48]; for example, those with stroke and 
comorbid arthritis may find physiotherapy sessions more challenging [49,50]. Fourth, 
multimorbid patients who become overburdened, for example by complex medication 
regimens, may be less likely to adhere to therapies, leading to poor disease control and a 
further escalation of treatments by health professionals, further increasing treatment burden 
[3,9,51]. While many pharmacological therapies may be beneficial for those with stroke, a 
key question is whether people with stroke have made informed decisions regarding whether 
or not to take so many medications, given their modest benefits. Although perceived 
treatment burden and capacity to cope with any given treatment burden will vary, we would 
recommend that patients with stroke are made aware of the relative benefits of their drugs, 
and are empowered to make their own decision whether to take them. 
Acknowledging and addressing treatment burden in stroke, particularly for those with 
multimorbidity, may improve the patient experience, adherence to therapies, and health 
outcomes [48]. Minimising unnecessary treatments, improving co-coordination of services 
and making care more patient-centred [23] are likely to lessen treatment burden, but will 
necessitate changes from policy level down to the individual consultation [3,48,52,53]. Most 
stroke management guidelines fail to mention multimorbidity, or merely acknowledge the 
more common comorbidities briefly with a lack of practical advice for clinicians [45,54–57]. 
We found only one stroke guideline that acknowledged the issue of polypharmacy, and again, 
detailed practical help was lacking [56]. This issue has been gaining prominence [58,59]. 
Guidelines should be redesigned to take account of comorbidity and treatment burden; for 
example, by providing guidance on potential interactions from drug combinations commonly 
prescribed for those with stroke and multimorbidity. and how to deal with the possible side 
effects or interactions that may arise [47]. In the current study, 21.9% of people with stroke 
had a painful condition, 20.7% had depression and 13.0% had atrial fibrillation, increasing 
the risk of being prescribed non-steroidal anti-infammatory drugs (NSAIDs), anti-
depressants, anti-platelet therapies and anti-coagulants concomitantly, which increases risk of 
adverse events, such as bleeding. Care pathways should be structured around the patient 
themselves, rather than the individual conditions, using a more generalist approach that 
considers issues such as multimorbidity as well as the individual’s support network and 
financial resources [9,60,61]. 
Strengths and limitations 
This analysis was undertaken using data from a large, nationally representative, primary care 
sample, and as far as we are aware, this is the first study on such a scale to examine 
multimorbidity and polypharmacy in stroke. This sample is representative of the Scottish 
population [37]; however, it may not reflect experience in other countries and healthcare 
systems. The prevalence of stroke in this sample was similar to that shown in other studies 
[44,62], further validating the data; however, the data were collected for clinical rather than 
research purposes. No standard methods for measuring multimorbidity or polypharmacy 
exist, therefore a pragmatic approach was taken. We examined thirty nine long-term 
conditions, which is substantially more than in previous studies. The rationale for including 
the conditions examined and the rules for identifying the presence of each were described in 
detail by the team who previously collated the data [1]. In addition, any medications bought 
over the counter or given from secondary care were not included. However, at the time of the 
analysis, prescriptions to people over sixty five years of age and to many people with chronic 
conditions were all free, with others being able to cap their out-of-pocket costs, thus 
suggesting a financial incentive to obtain medication via the primary care practice. 
As this is a cross-sectional study, the data we have were taken from one particular point in 
time, and therefore no conclusions about temporality or causation can be made. The measure 
of comorbidity was unweighted, as the aim was to be descriptive rather than to assess 
outcomes. This was deemed to be the most appropriate method, and is similar to that used by 
others investigating the prevalence of multimorbidity [1], but could be viewed as a limitation, 
especially as there may be a qualitative difference between the effects on perceived treatment 
burden of long-term conditions that produce regular symptoms (for example, heart failure) 
and those that are asymptomatic (for example, hypertension). We have no information about 
stroke severity, which is also a potential limitation. It should also be noted that due to the 
nature of the study, multiple analyses were carried out. Thus, the large numbers of cases and 
controls assessed in this study may have identified some associations that were statistically 
significant but not necessarily clinically significant; for example, for conditions such as 
cancer, glaucoma and asthma, which had ORs between 1.08 and 1.10 but were statistically 
significant with P < 0.001. 
Lastly, to explore treatment burden in stroke, this study examined multimorbidity and 
polypharmacy, however there are many more aspects of treatment burden still to be 
examined, such as clinic visits, continuity, coordination of care, and financial burden of 
therapies. The development of a patient-reported measure would enable a more detailed 
examination of treatment burden in stroke from the patient perspective. 
Conclusion 
In this study, we found that multimorbidity and polypharmacy were strikingly more common 
in those with stroke than those without. Polypharmacy can be thought of as a direct measure 
of one aspect of treatment burden, and we would suggest that people with stroke should be 
made aware of the relative benefits of their drugs so they can make informed decisions about 
therapeutic regimens. Both polypharmacy and multimorbidity are likely to be proxy markers 
for other aspects of treatment burden, as patients face the demands of managing multiple 
medications and conditions simultaneously. Clinical guidelines for stroke need to place 
greater emphasis on the management of multimorbidity, and further investigation of 
treatment burden in stroke is required to inform redesign of health services to improve patient 
outcomes. 
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